인플루엔자 백신 시장 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Influenza Vaccines Market was valued at USD 9 billion in 2025 and is estimated to grow at a CAGR of 7% to reach USD 17.4 billion by 2035.

The influenza vaccines market represents the global ecosystem dedicated to the development, production, and distribution of vaccines that help protect populations from circulating influenza viruses. These vaccines are designed to lower infection rates, minimize the severity of illness, and strengthen community-level immunity, particularly among individuals who are more vulnerable to complications. Various vaccine technologies are utilized across the industry, including multiple immunization platforms developed to improve immune protection and respond to evolving viral strains. A notable industry trend involves the transition toward advanced vaccine development technologies aimed at improving production efficiency and immunogenic performance. Traditional production methods are increasingly supported by modern manufacturing platforms that enable improved antigen matching, higher output levels, and more flexible production timelines. Government-backed immunization initiatives and institutional procurement programs are also supporting long-term demand growth. Public health policies that promote annual vaccination, combined with national stockpiling programs and broader healthcare coverage, are encouraging consistent vaccine uptake. These policy frameworks continue to stimulate investment in research, development, and manufacturing capacity while addressing longstanding challenges related to vaccine effectiveness and production timelines.

The inactivated segment held 85.7% share in 2025 and is projected to grow at a CAGR of 6.9% throughout 2026-2035. This segment maintains a leading position due to its well-established safety record and broad applicability across diverse population groups. Inactivated influenza vaccines remain widely utilized in immunization programs because they generate protective immune responses without introducing replicating viral particles. Their safety profile makes them suitable for use across a wide demographic range, including individuals with varying health conditions, which reinforces their widespread adoption within national vaccination strategies.

The quadrivalent vaccine segment generated USD 7.9 billion in 2025. These vaccines dominate the segment because they provide expanded protection against multiple circulating influenza virus strains within a single formulation. Broader strain coverage helps reduce the risk of mismatch between vaccine composition and seasonal viral patterns, which improves the overall effectiveness of vaccination campaigns. This expanded protective capability has made quadrivalent vaccines a preferred choice for large-scale immunization initiatives. In addition, the ability of these vaccines to address seasonal variability contributes to improved clinical outcomes, lower hospitalization rates, and stronger public health protection during influenza seasons.

North America Influenza Vaccines Market accounted for 44.9% share in 2025. The region maintains its strong position due to its advanced healthcare infrastructure, supportive regulatory frameworks, and high public awareness regarding preventive healthcare practices. The leadership of United States within the regional market is reinforced by well-established disease surveillance systems and healthcare policies that encourage routine vaccination. Public health programs that promote annual influenza vaccination across broad population groups continue to support strong demand, contributing to consistent market expansion across pediatric, adult, and high-risk populations.

Key participants operating in the Global Influenza Vaccines Market include Sanofi, GlaxoSmithKline, AstraZeneca, CSL Seqirus, Serum Institute of India, Sinovac Biotech, SK Bioscience, Viatris, GC Biopharma, Bharat Biotech, Cadila Healthcare (Zydus Lifesciences), Denka Seiken, and Bio Farma. Companies operating in the Global Influenza Vaccines Market are implementing several strategies to strengthen their competitive presence and expand market share. Leading vaccine manufacturers are investing heavily in research and development to advance next-generation vaccine platforms that offer improved immune responses and faster production capabilities. Strategic partnerships with government health agencies and international health organizations are helping companies secure large procurement contracts and strengthen supply networks. Firms are also expanding manufacturing capacity and adopting advanced production technologies to support large-scale vaccination programs. In addition, companies are increasing their focus on global distribution infrastructure and regional market expansion to improve vaccine accessibility.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Vaccine type trends
  • 2.2.3 Indication trends
  • 2.2.4 Flu type trends
  • 2.2.5 Age group trends
  • 2.2.6 Route of administration trends
  • 2.2.7 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of influenza
    • 3.2.1.2 Rising government health initiatives and immunization programs
    • 3.2.1.3 Advancements in vaccine technologies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost associated with vaccine development
    • 3.2.2.2 Longer vaccine production timelines
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of universal and broader-spectrum influenza vaccines
    • 3.2.3.2 Growth in pediatric and maternal immunization programs
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by Primary Research)
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Pipeline analysis
• 3.6 Patent analysis
• 3.7 Technology and innovation landscape (Driven by Primary Research)
  • 3.7.1 Current technologies
  • 3.7.2 Emerging technologies
• 3.8 Future market trends (Driven by Primary Research)
• 3.9 Impact of AI and generative AI on the market
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Inactivated
• 5.3 Live attenuated
• 5.4 Recombinant

Chapter 6 Market Estimates and Forecast, By Indication, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Quadrivalent
• 6.3 Trivalent

Chapter 7 Market Estimates and Forecast, By Technology, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Egg-based
• 7.3 Cell-based
• 7.4 Recombinant technology

Chapter 8 Market Estimates and Forecast, By Flu Type, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Seasonal
• 8.3 Pandemic

Chapter 9 Market Estimates and Forecast, By Age Group, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Pediatric
• 9.3 Adults

Chapter 10 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 Injection
• 10.3 Nasal spray

Chapter 11 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 11.1 Key trends
• 11.2 Hospitals
  • 11.2.1 Public
  • 11.2.2 Private
• 11.3 Clinics
• 11.4 Other end users

Chapter 12 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 12.1 Key trends
• 12.2 North America
  • 12.2.1 U.S.
  • 12.2.2 Canada
• 12.3 Europe
  • 12.3.1 Germany
  • 12.3.2 UK
  • 12.3.3 France
  • 12.3.4 Spain
  • 12.3.5 Italy
  • 12.3.6 Netherlands
• 12.4 Asia Pacific
  • 12.4.1 China
  • 12.4.2 India
  • 12.4.3 Japan
  • 12.4.4 Australia
  • 12.4.5 South Korea
• 12.5 Latin America
  • 12.5.1 Brazil
  • 12.5.2 Mexico
  • 12.5.3 Argentina
• 12.6 Middle East and Africa
  • 12.6.1 South Africa
  • 12.6.2 Saudi Arabia
  • 12.6.3 UAE

Chapter 13 Company Profiles

• 13.1 AstraZeneca
• 13.2 Bharat Biotech
• 13.3 Cadila Healthcare (Zydus Lifesciences)
• 13.4 CSL Seqirus
• 13.5 Denka Seiken
• 13.6 GlaxoSmithKline
• 13.7 Sanofi
• 13.8 Serum Institute of India
• 13.9 Sinovac Biotech
• 13.10 SK bioscience
• 13.11 Viatris
• 13.12 GC Biopharma
• 13.13 Bio Farma